Editors' view: Cancer pharmacotherapy: 21st Century 'magic bullets' and changing paradigms

British Journal of Clinical Pharmacology

Volumn 62, Issue 1, 2006, Pages 1-4

  Lewis, L D ^a  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 HYDROXYMETHOTREXATE; ANTINEOPLASTIC AGENT; CARBOPLATIN; CHECKPOINT KINASE 1; CHLORMETHINE; CISPLATIN; DIHYDROPYRIDINE DERIVATIVE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROURACIL; FOLIC ACID ANTAGONIST; GLUCURONOSYLTRANSFERASE; IMATINIB; LANSOPRAZOLE; MERCAPTOPURINE; METHOTREXATE; OMEPRAZOLE; PACLITAXEL; PHOSPHOTRANSFERASE INHIBITOR; TAXANE DERIVATIVE; THIOPURINE METHYLTRANSFERASE; THYMIDYLATE SYNTHASE; TIPIFARNIB; VINCA ALKALOID;

ACUTE LYMPHOBLASTIC LEUKEMIA; AREA UNDER THE CURVE; BREAST CANCER; CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER REGRESSION; CANCER SURVIVAL; CHORIOCARCINOMA; CHRONIC MYELOID LEUKEMIA; DISEASE ASSOCIATION; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DETERMINATION; DRUG DISPOSITION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG TARGETING; DRUG TOLERABILITY; EDITORIAL; ENDOMETRIUM CANCER; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HISTORY; HODGKIN DISEASE; HUMAN; LIQUID CHROMATOGRAPHY; LYMPH NODE METASTASIS; LYMPHOMA; LYMPHOSARCOMA; MASS SPECTROMETRY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PHILADELPHIA 1 CHROMOSOME; POPULATION RESEARCH; PRIORITY JOURNAL; SOLID TUMOR; TESTIS CANCER;

EID: 33746912320     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2006.02721.x     Document Type: Editorial

References (33)

1. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med 2004; 10: 789-99.
2. PhRMA website: http://www.Phrma.org/files/Cancer%20Survey.pdf. (last accessed 28 May 2006).
3. International HapMap Consortium. A haplotype map of the human genome. Nature 2005; 437: 1299-320.
4. International HapMap Project. http://www.hapmap.org. (last accessed 28 May 2006).
5. O'Shaughnessy KM. HapMap, pharmacogenomics, and the goal of personalized prescribing. Br J Clin Pharmacol 2006; 61: 783-86.
6. Innocenti F, Undevia SD, Iyer L, Chen PX, Das S, Kocherginsky M, Karrison T, Janisch L, Ramirez J, Rudin CM, Vokes EE, Ratain MJ. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol 2004; 22: 1382-8.
7. http://www.s2ortho.com/z-knowledge/pharaonic/medicin... (last accessed: 28 May 2006).
8. Breasted JH. The Edwin Smith surgical papyrus. Chicago: Chicago University Press, 1930.
9. Gilman A. The biological actions and therapeutic applications of the beta-chloroethyl amines and sulfides. Science 1946; 103: 409-36.
10. Goodman LS, Wintrobe MM, Dameshek W, Goodman MJ, Gilman A, McLennan MT. Nitrogen mustard therapy. Use of methyl-bis(betachloroethyl) amine hydrochloride and tris(beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders. JAMA 1946; 132: 126-32.
11. Gilman A. The initial clinical trial of nitrogen mustard. Am J Surg 1963; 105: 574-8.
12. Chabner BA, Roberts TG Jr. Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer 2005; 5: 65-72.
13. Schwartz RS. Paul Ehrlich's magic bullets. N Engl J Med 2004; 350: 1079-80.
14. Albert A. Selective toxicity. Nature 1950; 165 (4184): 12-16.
15. O'Hare T, Corbin AS, Druker BJ. Targeted CML therapy: controlling drug resistance, seeking cure. Curr Opin Genet Dev 2006; 16: 92-9.
16. Eastman A, Perez RP. New targets and challenges in the molecular therapeutics of cancer. Br J Clin Pharmacol 2006; 62: 5-14.
17. Kummar S, Gutierrez M, Doroshow JH, Murgo AJ. Drug development in oncology: classical cytotoxics and molecularly targeted agents. Br J Clin Pharmacol 2006; 62: 15-26.
18. Boddy AV. Recent developments in the clinical pharmacology of classical cytotoxic chemotherapy. Br J Clin Pharmacol 2006; 62: 27-34.
19. Yong WP, Innocenti F, Ratain MJ. The role of pharmacogenetics in cancer therapeutics. Br J Clin Pharmacol 2006; 62: 35-46.
20. Ralph LD, Sandstrom M, Twelves C, Dobbs NA, Thompson AH. Assessment of the validity of a population pharmacokinetic model of epirubicin. Br J Clin Pharmacol 2006; 62: 47-55.
21. Mould DR, Fleming GF, Darcy KM, Spriggs D. Population analysis of a 24-hour paclitaxel infusion in advanced endometrial cancer: a gynecologic oncology group study. Br J Clin Pharmacol 2006; 62: 56-70.
22. Bruno R, Olivares R, Berille J, Chaikin P, Vivier N, Hammershaimb L, Rhodes GR, Rigas JR. Alpha-1-acid glycoprotein as an independent predictor for treatment effects and a prognostic factor of survival in patients with non-small cell lung cancer treated with docetaxel. Clin Cancer Res 2003; 9: 1077-82.
23. Joerger M, Huitema ADR, van den Bongard HJGD, Baas P, Schornagel JH, Schellens JHM, Beijnen JH. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol 2006; 62: 71-80.
24. Breedveld P, Zelcer N, Pluim D, Sonmezer O, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P, Schellens JH. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res 2004; 64: 5804-11.
25. Perez-Ruixo JJ, Piotrovskij V, Zhang S, Hayes S, De Porre P, Zannikos P. Population pharmacokinetics of tipifarnib in healthy subjects and adult cancer patients. Br J Clin Pharmacol 2006; 62: 81-96.
26. Widmer N, Decosterd LA, Csajka C, Leyvraz S, Duchosal MA, Rosselet A, Rochat B, Eap CB, Henry H, Biollaz J, Buclin T. Population pharmacokinetics of imatinib and the role of alpha-1-acid glycoprotein. Br J Clin Pharmacol 2006; 62: 97-112.
27. Schmidli H, Peng B, Riviere GJ, Capdeville R, Hensley M, Gathmann I, Bolton AE, Racine-Poon A; IRIS Study Group. Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study. Br J Clin Pharmacol 2005; 60: 35-44.
28. Judson I, Ma P, Peng B, Verweij J, Racine A, di Paola ED, van Glabbeke M, Dimitrijevic S, Scurr M, Dumez H, van Oosterom A. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 2005; 55: 379-86.
29. Kretz O, Weiss HM, Schumacher MM, Gross G. In vitro blood distribution and plasma protein binding of the tyrosine kinase inhibitor imatinib and its active metabolite, CGP74588, in rat, mouse, dog, monkey, healthy humans and patients with acute lymphatic leukaemia. Br J Clin Pharmacol 2004; 58: 212-16.
30. Gambacorti-Passerini C, Zucchetti M, Russo D, Frapolli R, Verga M, Bungaro S, Tornaghi L, Rossi F, Pioltelli P, Pogliani E, Alberti D, Corneo G, D'Incalci M. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003; 9: 625-32.
31. Aarons L. Physiologically based pharmacokinetic modelling: a sound mechanistic basis is needed. Br J Clin Pharmacol 2005; 60: 581-83.
32. Sparano JA, Fazzari MJ, Childs G. Clinical application of molecular profiling in breast cancer. Future Oncol 2005; 1: 485-96.
33. Osieka R. Oncology. Arzneimittelforschung 1997; 47: 1161-65.